US pharmaceutical company Eli Lilly and Co (Lilly) (NYSE:LLY) will stop testing one of its experimental monoclonal antibody treatments in hospitalised COVID-19 patients after a review of results show it did not seem to be helping them, CNN reported on Tuesday.
The company stated that it would continue testing the treatment in patients with mild or moderate COVID-19 disease and would continue testing it as part of a dual-antibody therapy.
Reportedly, the monoclonal antibody, called bamlanivimab, was being tested in hospitalised patients in a clinical trial run by the National Institute of Allergy and Infectious Diseases.
Based on results reviewed on 26 October 2020 that showed patients were not helped by this single antibody treatment, no additional COVID-19 hospitalised patients will get it going forward, Lilly said.
There did not appear to be any safety issues and all the other studies looking at this antibody treatment will continue, Lilly added.
Currently, a trail looking at the impact this antibody treatment could have on patients who have been recently diagnosed with Covid-19 or who have moderate or mild cases is on going.
Also, there is another trial that is looking at its use in combination with a second monoclonal antibody the company calls etesevimab in that same patient population who are early in the course of their disease.
In addition, doctors are testing bamlanivimab on its own to prevent COVID-19 infection in residents and staff in long-term care facilities.
In October 2020, Lilly had filed a request with the US Food and Drug Administration for emergency use authorisation of bamlanivimab in patients with mild to moderate cases of COVID-19.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial